Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

被引：6

作者：

Jacques, Sarah K. ^{[1
,2
]}

McKeown, Janet ^{[3
]}

Grover, Piyush ^{[3
]}

Johson, Douglas B. ^{[4
]}

Zaremba, Anne ^{[5
]}

Dimitriou, Florentia ^{[6
,7
]}

Weiser, Roi ^{[24
]}

Farid, Mohamad ^{[8
]}

Namikawa, Kenjiro ^{[9
]}

Sullivan, Ryan J. ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Lebbe, Celeste ^{[12
]}

Hamid, Omid ^{[13
]}

Zager, Jonathan S. ^{[14
]}

Michielin, Olivier ^{[15
]}

Neyns, Bart ^{[16
]}

Nakamura, Yasuhiro ^{[17
]}

Robert, Caroline ^{[18
,19
]}

Mehnert, Janice ^{[25
]}

Ascierto, Paolo A. ^{[26
]}

Bhave, Prachi ^{[23
]}

Park, Benjamin ^{[4
]}

Zimmer, Lisa ^{[5
]}

Mangana, Joanna ^{[6
,11
]}

Mooradian, Megan ^{[10
]}

Placzke, Joanna ^{[7
]}

Allayous, Clare ^{[12
]}

Oliva, Isabella C. Glitza ^{[24
]}

Mehmi, Inderjit ^{[13
]}

Depalo, Danielle ^{[14
]}

Wicky, Alexandre ^{[15
]}

Schwarze, Julia K. ^{[16
]}

Roy, Severine ^{[18
]}

Boatwright, Christina ^{[25
]}

Vanella, Vito ^{[26
]}

Long, Georgina, V ^{[3
,20
,21
]}

Menzies, Alexander M. ^{[3
,20
,21
,22
]}

Lo, Serigne N. ^{[3
,20
]}

Carlino, Matteo S. ^{[1
,2
,3
,27
]}

机构：

[1] Westmead Hosp, Dept Med Oncol, Sydney, Australia

[2] Blacktown Hosp, Dept Med Oncol, Sydney, Australia

[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia

[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[5] Univ Hosp Essen, Dept Dermatol Venereol & Allergol, Essen, Germany

[6] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

[7] Univ Zurich, Fac Med, Zurich, Switzerland

[8] Natl Canc Ctr, Singapore, Singapore

[9] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[10] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[12] Univ Paris Cite, St Louis Hosp, Canc Inst AP HP Nord Paris Cite, INSERM U976,AP HP Dermatooncol, Paris, France

[13] Angeles Clin, Los Angeles, CA USA

[14] Moffit Canc Ctr, Dept Cutaneous Oncol, Tampa, FL USA

[15] Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland

[16] Univ Ziekenhuis Brussel, Brussels, Belgium

[17] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Skin Oncol Dermatol, Saitama, Japan

[18] Inst Gustave Roussy, Villejuif, France

[19] Paris Saclay Univ, Villejuif, France

[20] Univ Sydney, Fac Med & Hlth, Sydney, Australia

[21] Royal North Shore Hosp, Sydney, Australia

[22] Mater Hosp, Sydney, Australia

[23] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia

[24] MD Anderson Canc Ctr, Houston, TX USA

[25] NYU Langone, New York, NY USA

[26] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy

[27] Westmead Hosp, Crown Princess Mary Canc Ctr, 166-174 Hawkesbury Rd, Westmead, NSW 2145, Australia

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 199卷

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Acral melanoma; Mucosal melanoma; Adjuvant; Immunotherapy; Anti-PD1; IMMUNE CHECKPOINT INHIBITORS;

D O I：

10.1016/j.ejca.2024.113563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. Objective: To determine the efficacy of adjuvant PD1 in resected AM or MM. Design: An international, retrospective cohort study Setting: Data up to November 2021 collected from 20 centres across 10 countries. Participants: One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. Main outcomes and measures: Recurrence -free survival (RFS), distant metastasis -free survival (DMFS) and overall survival (OS) were investigated. Results: Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR -0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p -value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p -value 0.3799], DMFS or OS. Conclusion and relevance: After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.

引用

页数：8

共 22 条

[11] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Lian, B.
Si, L.
Chi, Z. H.
Sheng, X. N.
Kong, Y.
Wang, X.
Tian, H.
Li, K.
Mao, L. L.
Bai, X.
Tang, B. X.
Yan, X. Q.
Li, S. M.
Zhou, L.
Dai, J.
Tang, X. W.
Ran, F. W.
Yao, S.
Guo, J.
Cui, C. L.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
[12] Lian B, 2023, J Clin Oncol, V41, P9508, DOI [10.1200/JCO.2023.41.16_suppl.9508, DOI 10.1200/JCO.2023.41.16_SUPPL.9508]
[13] Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients
Maeda, T.
Yoshino, K.
Nagai, K.
Oaku, S.
Kato, M.
Hiura, A.
Hata, H.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1230 - 1231
[14] Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Nakamura, Y.
Namikawa, K.
Yoshino, K.
Yoshikawa, S.
Uchi, H.
Goto, K.
Fukushima, S.
Kiniwa, Y.
Takenouchi, T.
Uhara, H.
Kawai, T.
Hatta, N.
Funakoshi, T.
Teramoto, Y.
Otsuka, A.
Doi, H.
Ogata, D.
Matsushita, S.
Isei, T.
Hayashi, T.
Shibayama, Y.
Yamazaki, N.
[J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1198 - 1206
[15] Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Newel, Felicity
Kong, Yan
Wilmott, James S.
Johansson, Peter A.
Ferguson, Peter M.
Cui, Chuanliang
Li, Zhongwu
Kazakoff, Stephen H.
Burke, Hazel
Dodds, Tristan J.
Patch, Ann-Marie
Nones, Katia
Tembe, Varsha
ShanG, Ping
van der Weyden, Louise
WongH, Kim
Holmes, Oliver
Lo, Serigne
Leonardl, Conrad
Wood, Scott
Xu, Qinying
Rawson, Robert, V
Mukhopadhyay, Pamela
Dummer, Reinhard
Levesque, Mitchell P.
Jonsson, Goran
Wang, Xuan
Yeh, Iwei
Wu, Hong
Joseph, Nancy
Bastian, Boris C.
Long, Georgina, V
Spillane, Andrew J.
Shannon, Kerwin F.
Thompson, John F.
Saw, Robyn P. M.
Adams, David J.
Si, Lu
Pearson, John, V
Hayward, Nicholas K.
Waddell, Nicola
Mann, Graham J.
Guo, Jun
Scolyer, Richard A.
[J]. NATURE COMMUNICATIONS, 2019, 10 (1)
[16] Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Newell, Felicity
Wilmott, James S.
Johansson, Peter A.
Nones, Katia
Addala, Venkateswar
Mukhopadhyay, Pamela
Broit, Natasa
Amato, Carol M.
Van Gulick, Robert
Kazakoff, Stephen H.
Patch, Ann-Marie
Koufariotis, Lambros T.
Lakis, Vanessa
Leonard, Conrad
Wood, Scott
Holmes, Oliver
Xu, Qinying
Lewis, Karl
Medina, Theresa
Gonzalez, Rene
Saw, Robyn P. M.
Spillane, Andrew J.
Stretch, Jonathan R.
Rawson, Robert V.
Ferguson, Peter M.
Dodds, Tristan J.
Thompson, John F.
Long, Georgina V.
Levesque, Mitchell P.
Robinson, William A.
Pearson, John V.
Mann, Graham J.
Scolyer, Richard A.
Waddell, Nicola
Hayward, Nicholas K.
[J]. NATURE COMMUNICATIONS, 2020, 11 (01)
[17] The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
Ogata, Dai
Haydu, Lauren E.
Glitza, Isabella C.
Patel, Sapna P.
Tawbi, Hussein A.
McQuade, Jennifer L.
Diab, Adi
Ekmekcioglu, Suhendan
Wong, Michael K.
Davies, Michael A.
Amaria, Rodabe N.
[J]. CANCER MEDICINE, 2021, 10 (07): : 2293 - 2299
[18] Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
van Not, Olivier J.
de Meza, Melissa M.
van den Eertwegh, Alfons J. M.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
van Breeschoten, Jesper
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Ismail, Rawa K.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Stevense-den Boer, Marion A. M.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
Bonenkamp, Han J.
Boers-Sonderen, Marye J.
Blokx, Willeke A. M.
Wouters, Michel W. J. M.
Suijkerbuijk, Karijn P. M.
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 167 : 70 - 80
[19] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Weber, J.
Mandala, M.
Del Vecchio, M.
Gogas, H. J.
Arance, A. M.
Cowey, C. L.
Dalle, S.
Schenker, M.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Grob, J-J.
Butler, M. O.
Middleton, M. R.
Maio, M.
Atkinson, V.
Queirolo, P.
Gonzalez, R.
Kudchadkar, R. R.
Smylie, M.
Meyer, N.
Mortier, L.
Atkins, M. B.
Long, G. V.
Bhatia, S.
Lebbe, C.
Rutkowski, P.
Yokota, K.
Yamazaki, N.
Kim, T. M.
de Pril, V.
Sabater, J.
Qureshi, A.
Larkin, J.
Ascierto, P. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) : 1824 - 1835
[20] Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Weber, Jeffrey S.
Schadendorf, Dirk
Del Vecchio, Michele
Larkin, James
Atkinson, Victoria
Schenker, Michael
Pigozzo, Jacopo
Gogas, Helen
Dalle, Stephane
Meyer, Nicolas
Ascierto, Paolo A.
Sandhu, Shahneen
Eigentler, Thomas
Gutzmer, Ralf
Hassel, Jessica C.
Robert, Caroline
Carlino, Matteo S.
Di Giacomo, Anna Maria
Butler, Marcus O.
Munoz-Couselo, Eva
Brown, Michael P.
Rutkowski, Piotr
Haydon, Andrew
Grob, Jean-Jacques
Schachter, Jacob
Queirolo, Paola
de la Cruz-Merino, Luis
Haydon, Andrew
Grob, Jean-Jacques
Schachter, Jacob
Queirolo, Paola
De La Cruz-Merino, Luis
van der Westhuizen, Andre
Menzies, Alexander M.
Re, Sandra
Bas, Tuba
de Pril, Veerle
Braverman, Julia
Tenney, Daniel J.
Tang, Hao
Long, Georgina, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 517 - +

← 1 2 3 →